Mayo Clinic
Departments of Epidemiology and Neurology
Michelle M. Mielke, Ph.D. is currently Professor of Epidemiology and Professor of Neurology at the Mayo Clinic. She is also the Associate Chair of Faculty Development and Academic Affairs in the Department of Quantitative Health Sciences. Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative and other aging-related diseases. One focus of her research is the identification of fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease and other neurodegenerative diseases. Another focus of Dr. Mielke’s research is on understanding sex and gender differences in the development and progression of Alzheimer’s disease and of other aging-related conditions. She directs the Mayo Clinic Specialized Center of Research Excellence (SCORE) on Sex Differences. Dr. Mielke is co-Chair of the Sex and Gender Diversity Significant Interest Group for the Alzheimer’s Association Professional Interest Area. She received the John R. Raymond Mentor Award from the Women Scholars Initiative. She is the PI of several NIH- and Foundation-funded clinical- and epidemiological-based grants and has published over 350 manuscripts.

Moderator of 2 Sessions

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE PLENARY: 115-117
Session Type
SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
02:45 PM - 04:45 PM
Room
ONSITE: 113

Presenter of 2 Presentations

MasterClass 1: A Call to Action to Improve the Early Detection and Diagnosis of AD in the Era of Disease-Modifying Therapies

PROGNOSTIC USE OF PLASMA PHOSPHORYLATED TAU FOR INCIDENT MILD COGNITIVE IMPAIRMENT AMONG COGNITIVELY UNIMPAIRED PARTICIPANTS

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE PLENARY: 115-117
Lecture Time
09:30 AM - 09:45 AM

Abstract

Aims

We examined plasma phosphorylated tau (P-tau) 181 and 217 as prognostic biomarkers of incident mild cognitive impairment (MCI) in a community-based study and assessed whether the prognostic value differed by elevated brain amyloid.

Methods

We included 999 cognitively unimpaired participants enrolled in the Mayo Clinic Study on Aging (median age of 73; 54% male, 25% APOE Ɛ4 carriers). P-tau 181 and 217 was measured on the MSD platform; previously developed cutpoints for P-tau181≥1.62 [P-tau181+] and P-tau217≥0.25 [P-tau217+]) were used for analyses. Cox Proportional Hazard models examined P-tau181+ and P-tau217+for risk of incident MCI within 2 years after adjusting for age, sex, APOE, chronic kidney disease, body mass index, stroke, and myocardial infarction. Elevated amyloid (A+) was defined as SUVR≥1.48 using PiB PET in 874 subjects. The risk of MCI among P-tau181+ and P-tau217+ was determined by brain amyloid status (A+ and A-).

Results

There were 64 incident cases of MCI within 2 years. Among all participants the P-tau measures performed similarly for risk of MCI at 2 years (P-tau181: HR 2.49, 95% CI: 1.47, 4.20; P-tau217: HR 2.24, 95% CI: 1.30, 3.85). Among those with amyloid PET, neither P-tau181+ (interactive p-value = 0.64) nor P-tau217+ (interactive p-value = 0.52) for risk of MCI differed by A+ status.

Conclusions

In this community-based sample of cognitively unimpaired participants, plasma P-tau levels can inform on risk of incident MCI within 2 years independent of amyloid PET status.

Hide